Novel agents for muscle-invasive and advanced urothelial cancer.
Conventional front-line platinum-based combination chemotherapy yields high response rates but suboptimal long-term outcomes for advanced urothelial cancer. Salvage therapy is an unmet need, with disappointing outcomes. The profusion of novel biological agents offers the promise of improved outcomes. Neoadjuvant therapy before cystectomy for muscle-invasive bladder cancer provides an important paradigm and an interesting approach in developing novel agents. Patients who are not candidates for cisplatin require special attention. A multidisciplinary approach and collaboration among laboratory scientists, oncologists, urologists and radiation oncologists is necessary to make therapeutic advances. Recent and ongoing trials of novel chemotherapeutic and biologic agents are reviewed.
Sonpavde
Guru
G
US Oncology Research, Baylor College of Medicine, Houston, TX 77598, USA. guru.sonpavde@usoncology.com
Ross
Robert
R
Powles
Thomas
T
Sweeney
Christopher J
CJ
Hahn
Noah
N
Hutson
Thomas E
TE
Galsky
Matthew D
MD
Lerner
Seth P
SP
Sternberg
Cora N
CN
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000556:secondary; D002986:Clinical Trials as Topic; D006801:Humans; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis / Q000188:drug therapy; D016896:Treatment Outcome; D014571:Urologic Neoplasms / Q000188:drug therapy* / Q000473:pathology